Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 6,604

Document Document Title
WO/2018/067704A1
The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.  
WO/2018/064119A1
Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.  
WO/2018/055235A1
The present invention concerns compounds of Formula 1a and its uses as a drug, particularly in treatment of cardiac diseases, and in methods and products relating to cell differentiation.  
WO/2018/053587A1
The present invention relates to novel compounds and their use in the prophylactic and/or therapeutic treatment of hypertension and/or fibrosis.  
WO/2018/050631A1
The present invention relates to novel compounds of general formula (I) wherein the groups X, and R1 to R4 have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preven...  
WO/2018/049328A1
Provided herein are compounds, compositions including them, and methods of modulating GPR120 activity and treating diseases mediated by GPR120 by administering such compounds and compositions.  
WO/2018/046337A1
The present invention discloses solid forms of ingenol 3-(3,5-diethylisoxazole-4-carboxylate) selected from an amorphous form or a crystalline anhydrous form. The invention also discloses solid solvates of ingenol 3-(3,5-diethylisoxazole...  
WO/2018/049324A1
Provided herein are compounds, compositions including them, and methods of modulating GPR120 activity and treating diseases mediated by GPR120 by administering such compounds and compositions.  
WO/2018/045149A1
Disclosed are compounds of Formula (I), Formula (II), Formula (III), and Formula (IV) or salts thereof, wherein R2 is -OH or -OP(O)(OH)2; and R1 is defined herein. Also disclosed are methods of using such compounds as selective agonists ...  
WO/2018/029150A1
The invention relates to compounds acting as agonists of G-protein coupled receptor 120 (GPR120) and/or 40 (GPR40), and having formula (I). Said compounds are useful in the treatment of diseases or disorders modulated by GPR120 and/or GP...  
WO/2018/024188A1
Provided are a polycyclic compound and a manufacturing method, pharmaceutical composition, and application thereof. The structure of the polycyclic compound and an isomer, prodrug, solvate, hydrate, stable isotopic derivative, or pharmac...  
WO/2018/026997A1
The present invention relates to- chimeric (including Afunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic and other cancers where cancer ...  
WO/2018/024224A1
A nitrogen-containing tricyclic compound which acts as modulator of FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the ...  
WO/2018/026997A9
The present invention relates to- chimeric (including Afunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic and other cancers where cancer ...  
WO/2018/018091A1
The present invention relates to compounds and their use in the prophylactic and/or therapeutic treatment of pulmonary fibrosis and/or related conditions.  
WO/2018/014858A1
Provided are a crystal and salt of an m-dihydroxybenzene represented by (I), a manufacturing method thereof, and an application of the crystal in preparing a pharmaceutical product for treating a HSP90-induced disease.  
WO/2018/001084A1
The present invention relates to the field of pharmaceutical chemistry. Disclosed are a heat shock protein inhibitor, and a manufacturing method and application thereof. The heat shock protein inhibitor has a characteristic structure rep...  
WO/2017/219083A1
The present invention relates to novel compounds which active HIV expression in latently infected cells. More particularly, the invention relates to pharmaceutical compositions comprising the novel compounds and their use in activating H...  
WO/2017/223188A1
The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.  
WO/2017/216705A1
The invention relates to a crystalline form of the (R)-4-(5- (cyclopropylethynyl)isoxazol-3-yl)-N-hydroxy-2-methyl-2- (methylsulfonyl)butanamide (i.e. the compound of formula (A)) with low hydroscopicity. The compound and compositions th...  
WO/2017/195216A1
The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and...  
WO/2017/195216A4
The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and...  
WO/2017/193034A1
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.  
WO/2017/191000A1
Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a di...  
WO/2017/193041A1
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.  
WO/2017/193063A1
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.  
WO/2017/187352A1
The invention relates to a new class of compounds of formula (I) targeting COX-1. The invention also relates to the use of some of such compounds as a tool to investigate the structure and function of the enzyme, in the treatment targeti...  
WO/2017/183723A1
The present invention addresses the problem of providing a novel compound having a strong opening action with respect to KCNQ 2-5 channels. Provided is a compound represented by the general formula (I) (in the formula, the definitions of...  
WO/2017/176948A1
This invention relates to processes for the preparation of antiparasitic isoxazoline compounds enriched in an enantiomer using quinine- based chiral phase transfer catalysts. The invention also relates to novel quinine-based phase transf...  
WO/2017/165256A1
The present disclosure relates to compounds of formula (I) that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly ...  
WO/2017/156009A1
In one aspect, the invention relates to a crystalline form of the structure: or a pharmaceutically acceptable salt thereof, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions co...  
WO/2017/153952A1
The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to Formula (I): wherein R, R1 and R2 are as defined herein, or a pharmaceutically acceptable salt thereof. ...  
WO/2017/155844A1
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A -Y -L-R (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function o...  
WO/2017/151018A1
The invention relates to the chemistry of organic compounds, pharmacology and medicine, and pertains to the prevention and/or treatment of a state in mammals characterized by undesirable thrombosis, and, in particular, thromboses, thromb...  
WO/2017/147047A1
The present disclosure is directed to modulators of farnesoid X receptor. Methods of making and using these modulators is also described.  
WO/2017/147352A1
This invention relates to long-acting injectable compositions for combating parasites in animals, comprising at least one isoxazoline active agent, a liquid PEG and/or a neutral oil, optionally a co-solvent, and optionally a pharmaceutic...  
WO/2017/136727A3
The present disclosure relates generally to N-azepinyl-carboxamide derivatives and compositions, and their use as inhibitors of receptor-interacting protein kinase 1 which is a key regulator of inflammation, apoptosis and necroptosis.  
WO/2017/133521A1
Provided in the present invention is a compound represented by the following general formula (1), a pharmaceutically acceptable salt thereof, ester thereof or stereoisomer thereof. Also provided in the present invention also are a method...  
WO/2017/128896A1
Disclosed are an FXR agonist and a preparation method and use thereof, in particular relating to the compound having the structure of formula (I), a stereisomer or a pharmaceutically acceptable salt thereof. The series of compounds can b...  
WO/2017/131221A1
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a and R4b are as defined in the specification, processes for their preparation, pharmaceutical compositions cont...  
WO/2017/108927A1
The invention discloses polymorphic forms of Ingenol 3-(3,5-diethylisoxazole-4-carboxylate), and a process for preparation of the polymorphic forms.  
WO/2017/096484A1
This present disclosure relates to the use of a cranberry extract rich in proanthocyanidins as antibiotic synergizing agent to mitigate multidrug resistance and biofilm formation in different pathogenic bacteria. The synergistic combinat...  
WO/2017/096301A1
The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.  
WO/2017/089389A1
The invention relates to a compound of formula (I) wherein R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used in the treatment of Human African TRypanosomiasis.  
WO/2017/071411A1
A crystalline form of isoxadifen-ethyl of formula (I), the crystal preparation process, the analyses of the crystal through various analytical methods and using the crystal to prepare stable agrochemical formulation are provided. The use...  
WO/2017/069601A1
The present invention relates to novel aminoalkylazoles acting as inhibitors of malarial protease plasmepsin II. These can be used as medicines or as constituent of medicines for the treatment of malaria infection.  
WO/2017/070084A1
The disclosed subject matter provides N- hydroxylsulfonamide derivative compounds of formulae (I), (II) or (III) as drawn below, pharmaceutical compositions comprising such compounds, kits comprising such compounds, and methods of using ...  
WO/2017/064512A1
Anti-angiogenic treatments, for example treatment of ocular neovascularization or cancer, treatments of hyperpermeability disorders, treatments of neuropathic and neurodegenerative disorders, pain treatments, methods of treating or preve...  
WO/2017/045751A1
The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as ASIC inhibitors.  
WO/2017/036404A1
Carboxy-substituted (hetero)aryl derivatives, pharmaceutical compositions comprising these compounds, and methods of preparing such compounds and compositions are provided. The compounds or compositions are useful in inhibiting xanthine ...  

Matches 1 - 50 out of 6,604